Omada Digital Diabetes Prevention Program Shows Sustained HbA1c Reduction and Weight Loss in Randomized Control Trial.
PREDICTS Trial Meets Primary and Secondary Endpoints, Demonstrates Omada's Program Delivers Meaningful Clinical Outcomes
The PREDICTS trial randomized 599 individuals with prediabetes to the Omada d-DPP or a single session diabetes prevention class. The Omada group received weekly sessions, lifestyle coaching, virtual peer support and behavior tracking tools for 12 months. The primary and secondary endpoints of the study were to detect changes in HbA1c and body weight at 12 months. Jeffrey Katula, PhD, Associate Professor of Health and Exercise Science at Wake Forest University and the study's co-Principal Investigator, presented the PREDICTS outcomes. The study endpoints of the trial were met and the intention-to-treat analysis revealed the following:
Omada participants on average reduced Hemoglobin A1c (HbA1c) by 0.23% at 12 months, a significantly greater reduction than the 0.15% seen in the comparison group (p-value<0.01);
Fifty-eight percent of Omada participants reduced their HbA1c to the normal range one year after beginning the program, versus 48% of the comparison group (p-value<0.04);
Omada participants achieved an average weight loss of 5.4% one year after enrollment, compared to 2% weight loss in the comparison group (p-value<.01);
Forty-four percent of Omada participants achieved weight loss of 5% or greater, versus 21% of comparison group participants (p-value<.01);
Among Omada participants in the study, age 65 and older:
Average HbA1c reduction was 0.28% at one year, significantly greater than the 0.14% reduction in the comparison group (p-value<.05); and
Average weight loss at 12 months was 6.1%, significantly greater than the 2.1% weight loss seen in the comparison group (p-value<.05).
Read more about the study from PRNewsWire HERE